Synthesis and crystal structure of a meloxicam co-crystal with benzoic acid

Binary Mixtures of Meloxicam and L-Tartaric Acid for Oral Bioavailability Modulation of Pharmaceutical Dosage Forms

“…In the literature, various meloxicam co-crystals have been reported with various carboxylic acids: 1-hydroxy-2-naphthoic acid, glutaric acid, L-malic acid, salicylic acid, fumaric acid, succinic acid, maleic acid, malonic acid, gentisic acid, 4-hydroxybenzoic, acid, adipic acid, (þ)-camphoric acid, glycolic acid, benzoic acid, DL-malic acid, hydro-cinnamic acid, ascorbic acid, acetyl salicylic acid [11,[14][15][16][17][18][19][20][21][22][23] and hydrosulphate monohydrate [21]. The physical chemical characterization methods of meloxicam mixtures were as follows: differential scanning calorimetry (DSC), Fourier Transform Infrared spectroscopy (FT-IR), X-ray diffraction (XRD), complemented by solubility, in vitro release and stability studies [6,8].…”

Pharmaceutical Salts of Piroxicam and Meloxicam with Organic Counterions

“…68 To date, the reports of cocrystals/salts of PRM or MEL with organic basic cocrystal/salt formers are rare, and the solid-state luminescent properties of PRM have not been reported. Therefore, one motivation for this study is to explore whether no improvement in solubility at pH 1.2, higher bioavailability and solubility at pH 6.8 norfloxacin MeOH 34 higher solubility at pH 6.8 (x 1.4) cocrystal/cocrystal solvate benzoic acid 35 increased solubility (x 3), increased dissolution rate in H 2 O (x 2) improved oral bioavailability in rats (x 15) clonixin ethyl acetate 36 improved moisture stability febuxostat 37 improved dissolution at pH 6.8 (x 2.8), improved flow and compressibility ferulic acid 38 improved IDR at pH 2 (x 1.7), improved powder flowability furosemide 39 good thermal stability, good stability under accelerated aging nicotinamide, b resorcinol, b saccharin sodium, b urea b, 40 no solubility advantage methylparaben, b vanillin b, 41 no solubility and IDR advantages at pH 1.2, superior dissolution rates in the sink condition at pH 1.2 saccharin 42 reduced plasticity and significantly deteriorated tableting behavior sodium acetate b, 40 improved solubility (x 5), improved flow and compressibility MEL salt/salt solvate 4-aminopyridine, 4-dimethylaminopyridine, piperazine (this work) higher solubility at pH 6.5 arginine b, 43,44 improved dissolution behavior at pH 1.2 (x 9.4) and 7.5 ciprofloxacin MeCN 34 higher solubility at pH 6.8 (x 3) cysteine, b glycine b, 43 improved dissolution behavior at pH 7.5 meglumine b, 45 improved solubility at pH 6 KOH H 2 O b, 46 improved dissolution behavior at pH 5.6, no bioavailability advantage in vivo di-/triethanolamine, b tris(hydroxymethyl)aminomethane, b KOH b, 44 improved dissolution behaviors at pH 1.2 (x 3.7−7.2) salt cocrystal L-malic acid 19,30 no solubility advantage at pH 6.5, improved bioavailability (x 1.2) cocrystal/cocrystal solvate adipic acid 30,47 no solubility advantage at pH 6.8 Aspirin 48 improved solubility at pH 7.4 (x 44), improved bioavailability (x 4.4) benzoic acid, 19,49 4-hydroxybenzoic acid, b,19,30 1-hydroxy-2-naphthoic acid, 19,30 D...…”